<VariationArchive RecordType="classified" VariationID="9410" VariationName="NM_000077.5(CDKN2A):c.226_244del (p.Ala76fs)" VariationType="Deletion" Accession="VCV000009410" Version="2" NumberOfSubmissions="2" NumberOfSubmitters="1" DateLastUpdated="2022-09-17" DateCreated="2019-11-29" MostRecentSubmission="2019-11-29">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="24449" VariationID="9410">
      <GeneList>
        <Gene Symbol="CDKN2A" FullName="cyclin dependent kinase inhibitor 2A" GeneID="1029" HGNC_ID="HGNC:1787" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>9p21.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="21967752" stop="21995324" display_start="21967752" display_stop="21995324" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="21967750" stop="21994489" display_start="21967750" display_stop="21994489" Strand="-" />
          </Location>
          <OMIM>600160</OMIM>
          <Haploinsufficiency last_evaluated="2022-03-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDKN2A">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-03-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDKN2A">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000077.5(CDKN2A):c.226_244del (p.Ala76fs)</Name>
      <CanonicalSPDI>NC_000009.12:21971114:CGGGTCGGGTGAGAGTGGC:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>9p21.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="21971115" stop="21971133" display_start="21971115" display_stop="21971133" variantLength="19" positionVCF="21971114" referenceAlleleVCF="ACGGGTCGGGTGAGAGTGGC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="21971114" stop="21971132" display_start="21971114" display_stop="21971132" variantLength="19" positionVCF="21971113" referenceAlleleVCF="ACGGGTCGGGTGAGAGTGGC" alternateAlleleVCF="A" />
      </Location>
      <OtherNameList>
        <Name>p16-Leiden</Name>
      </OtherNameList>
      <ProteinChange>A25fs</ProteinChange>
      <ProteinChange>A76fs</ProteinChange>
      <ProteinChange>R90fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_11" sequenceAccession="LRG_11">
            <Expression>LRG_11:g.28359_28377del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_11t1" sequenceAccession="LRG_11t1">
            <Expression>LRG_11t1:c.226_244del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_11p1" sequenceAccession="LRG_11p1" change="p.Ala76fs">
            <Expression>LRG_11p1:p.Ala76fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.11" sequenceAccession="NC_000009" sequenceVersion="11" change="g.21971114_21971132del" Assembly="GRCh37">
            <Expression>NC_000009.11:g.21971114_21971132del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.12" sequenceAccession="NC_000009" sequenceVersion="12" change="g.21971115_21971133del" Assembly="GRCh38">
            <Expression>NC_000009.12:g.21971115_21971133del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007485.1" sequenceAccession="NG_007485" sequenceVersion="1" change="g.28359_28377del">
            <Expression>NG_007485.1:g.28359_28377del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000077.5" sequenceAccession="NM_000077" sequenceVersion="5" change="c.226_244del" MANESelect="true">
            <Expression>NM_000077.5:c.226_244del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000068.1" sequenceAccession="NP_000068" sequenceVersion="1" change="p.Ala76fs">
            <Expression>NP_000068.1:p.Ala76fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001195132.2" sequenceAccession="NM_001195132" sequenceVersion="2" change="c.226_244del">
            <Expression>NM_001195132.2:c.226_244del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001182061.1" sequenceAccession="NP_001182061" sequenceVersion="1" change="p.Ala76fs">
            <Expression>NP_001182061.1:p.Ala76fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363763.2" sequenceAccession="NM_001363763" sequenceVersion="2" change="c.73_91del">
            <Expression>NM_001363763.2:c.73_91del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350692.1" sequenceAccession="NP_001350692" sequenceVersion="1" change="p.Ala25fs">
            <Expression>NP_001350692.1:p.Ala25fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_058195.4" sequenceAccession="NM_058195" sequenceVersion="4" change="c.269_287del" MANEPlusClinical="true">
            <Expression>NM_058195.4:c.269_287del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_478102.2" sequenceAccession="NP_478102" sequenceVersion="2" change="p.Arg90fs">
            <Expression>NP_478102.2:p.Arg90fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_058197.5" sequenceAccession="NM_058197" sequenceVersion="5" change="c.*149_*167del">
            <Expression>NM_058197.5:c.*149_*167del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA120386" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="600160.0003" DB="OMIM" />
        <XRef Type="rs" ID="587776716" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff reviewed the sequence information reported in PubMed 7670475 Fig. 3 to determine the location of this allele on the current reference sequence.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000077.5(CDKN2A):c.226_244del (p.Ala76fs) AND Melanoma, cutaneous malignant, susceptibility to, 2" Accession="RCV000010013" Version="6">
        <ClassifiedConditionList TraitSetID="2585">
          <ClassifiedCondition DB="MedGen" ID="C1835044">Melanoma, cutaneous malignant, susceptibility to, 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2012-06-01" SubmissionCount="1">risk factor</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000077.5(CDKN2A):c.226_244del (p.Ala76fs) AND Melanoma-pancreatic cancer syndrome" Accession="RCV000010015" Version="7">
        <ClassifiedConditionList TraitSetID="2587">
          <ClassifiedCondition DB="MedGen" ID="C1838547">Melanoma-pancreatic cancer syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2012-06-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2012-06-01" NumberOfSubmissions="2" NumberOfSubmitters="1" DateCreated="2019-11-29" MostRecentSubmission="2019-11-29">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic; risk factor</Description>
        <Citation Type="general">
          <ID Source="PubMed">10956390</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12549483</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7670475</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10400925</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22636603</ID>
        </Citation>
        <DescriptionHistory Dated="2022-03-18">
          <Description>Pathogenic, risk factor</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="2587" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2742" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Melanoma-pancreatic cancer syndrome</ElementValue>
                <XRef ID="Melanoma-pancreatic+cancer+syndrome/8812" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011713" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000325625" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501426" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000502978" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569524" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Melanoma-pancreatic cancer syndrome is an inherited cancer predisposition syndrome in which mutation carriers have an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer (summary by Harinck et al., 2012).
For background and phenotypic information on malignant melanoma and pancreatic cancer, see 155600 and 260350, respectively.</Attribute>
                <XRef Type="MIM" ID="606719" DB="OMIM" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <XRef ID="404560" DB="Orphanet" />
              <XRef ID="C1838547" DB="MedGen" />
              <XRef ID="MONDO:0011713" DB="MONDO" />
              <XRef Type="MIM" ID="606719" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2585" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5466" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cutaneous malignant melanoma 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Melanoma, cutaneous malignant, susceptibility to, 2</ElementValue>
                <XRef ID="MONDO:0007964" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CMM2</ElementValue>
                <XRef Type="MIM" ID="155601" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <XRef ID="618" DB="Orphanet" />
              <XRef ID="C1835044" DB="MedGen" />
              <XRef ID="MONDO:0007964" DB="MONDO" />
              <XRef Type="MIM" ID="155601" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="30234" SubmissionDate="2019-11-26" DateLastUpdated="2019-11-29" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="600160.0003_MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 2" title="CDKN2A, 19-BP DEL, NT225_MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 2" />
        <ClinVarAccession Accession="SCV000030234" DateUpdated="2019-11-29" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000030235" DateChanged="2016-03-06" Version="1" />
        </ReplacedList>
        <Classification DateLastEvaluated="2012-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>risk factor</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Gruis et al. (1995) analyzed CDKN2A coding sequences in 15 Dutch FAMMM syndrome pedigrees and identified a 19-bp germline deletion in 13 of them. All 13 families originated from an endogamous population. The deletion caused a reading-frame shift, predicted to result in a severely truncated p16 protein. Homozygosity for the deletion was found in 2 family members, one of whom showed no obvious signs of melanoma. The finding demonstrated that homozygotes for this CDKN2A mutation are viable, and suggested the presence of a genetic mechanism that can compensate for the functional loss of p16. The results strengthened the notion that p16 is the molecular nature of the 9p21-linked form of familial melanoma (CMM2; 155601). Of the 2 homozygous individuals, one was fully examined at the age of 54 and showed as the only possible sign of FAMMM 3 very mildly atypical nevi. Until her death from adenocarcinoma (site not stated) at the age of 55, this subject remained free of melanomas. The second homozygote, a nephew of the first, had a very large number of atypical moles at the age of 11; at the age of 15, an invasive melanoma was found.</Attribute>
              <Citation>
                <ID Source="PubMed">7670475</ID>
              </Citation>
              <XRef DB="OMIM" ID="155601" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">(In addition to the 19-bp deletion of p16, which is designated p16-Leiden, there is at least one familial hypercholesterolemia Leiden (143890.0041), factor V Leiden (612309.0001), apoE3 Leiden (107741.0006), and a hemoglobin Leiden (141900.0156).)</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Van der Velden et al. (1999) hypothesized that a tentative second tumor-related gene in 9p21 may also act as a modifier of melanoma risk conveyed by known CDKN2A mutations. To identify genetic modifiers for a known, 'primary' susceptibility gene, one would ideally need to study a large number of carriers of a single mutation in that primary gene. Dutch FAMMM families provided them with a unique opportunity for such studies, since the 19-bp founder deletion in exon 2 of the CDKN2A gene, p16-Leiden, segregated in most Dutch FAMMM families. The 36% cumulative incidence for melanoma in p16-Leiden carriers illustrated a high melanoma risk associated with this mutation but also suggested that environmental and/or genetic factors act as risk modifiers. Van der Velden et al. (1999) performed haplotype analysis for 9p21 using microsatellite markers in 6 p16-Leiden families originating from a founder population. In 2 families, p16-Leiden carriers shared an unexpectedly large founder haplotype (approximately 20 cM) around CDKN2A, mostly in the proximal direction. Melanoma-positive p16-Leiden carriers from these families showed this extensive proximal haplotype, compared with melanoma-negative p16-Leiden carriers from the same families. Additional p16-Leiden families less heavily affected with melanoma showed shorter haplotype sharing, excluding the region proximal of CDKN2A. The presence of a gene involved in melanoma susceptibility proximal to CDKN2A was corroborated by somatic deletions of 9p in tumors, which frequently did not include CDKN2A but a more proximal chromosomal region instead. The results provided a candidate region for further gene mapping in p16-negative 9p21-linked melanoma families and guided the search for risk modifiers in melanoma development.</Attribute>
              <Citation>
                <ID Source="PubMed">10400925</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Vasen et al. (2000) performed mutation analysis on 27 families with FAMMM syndrome and identified the CDKN2A-Leiden mutation in 19 families. They identified 86 patients with melanoma, and the second most frequent cancer was pancreatic carcinoma, which was observed in 15 patients from 7 families. The mean age at diagnosis of pancreatic carcinoma was 58 years, with a range from 38 to 77 years. Putative mutation carriers had an estimated cumulative risk of 17% for developing pancreatic carcinoma by age 75 years. In the 8 CDKN2A-Leiden-negative families, no cases of pancreatic carcinoma had occurred. The authors concluded that individuals with the CDKN2A-Leiden mutation show an enormous risk of developing pancreatic cancer (see 606719).</Attribute>
              <Citation>
                <ID Source="PubMed">10956390</ID>
              </Citation>
              <XRef DB="OMIM" ID="606719" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Schneider-Stock et al. (2003) found the p16-Leiden mutation in heterozygous state in the blood and all 3 tumors of a man who was diagnosed at age 54 years with simultaneous development of 3 carcinomas of the pharynx and oral cavity. The patient neither smoked more than 5 cigarettes daily nor abused alcohol. Both his parents and his only sister died of cancer very early (the mother of gynecologic cancer, the father of liver carcinoma, and the sister of leukemia).</Attribute>
              <Citation>
                <ID Source="PubMed">12549483</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Harinck et al. (2012) identified the Leiden mutation (225_243del) in 5 Dutch families ascertained for familial clustering of pancreatic cancer. Four of the families with the Leiden mutation had members who developed melanoma. In the fifth family, only pancreatic cancer segregated with mutation status; no cases of melanoma were noted. Harinck et al. (2012) concluded that the CDKN2A gene should be analyzed in families with pancreatic cancer, even if melanoma is not present.</Attribute>
              <Citation>
                <ID Source="PubMed">22636603</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDKN2A" />
          </GeneList>
          <Name>CDKN2A, 19-BP DEL, NT225</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">19-BP DEL, NT225</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="600160.0003" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="30236" SubmissionDate="2019-11-26" DateLastUpdated="2019-11-29" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="600160.0003_MELANOMA-PANCREATIC CANCER SYNDROME" title="CDKN2A, 19-BP DEL, NT225_MELANOMA-PANCREATIC CANCER SYNDROME" />
        <ClinVarAccession Accession="SCV000030236" DateUpdated="2019-11-29" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2012-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Gruis et al. (1995) analyzed CDKN2A coding sequences in 15 Dutch FAMMM syndrome pedigrees and identified a 19-bp germline deletion in 13 of them. All 13 families originated from an endogamous population. The deletion caused a reading-frame shift, predicted to result in a severely truncated p16 protein. Homozygosity for the deletion was found in 2 family members, one of whom showed no obvious signs of melanoma. The finding demonstrated that homozygotes for this CDKN2A mutation are viable, and suggested the presence of a genetic mechanism that can compensate for the functional loss of p16. The results strengthened the notion that p16 is the molecular nature of the 9p21-linked form of familial melanoma (CMM2; 155601). Of the 2 homozygous individuals, one was fully examined at the age of 54 and showed as the only possible sign of FAMMM 3 very mildly atypical nevi. Until her death from adenocarcinoma (site not stated) at the age of 55, this subject remained free of melanomas. The second homozygote, a nephew of the first, had a very large number of atypical moles at the age of 11; at the age of 15, an invasive melanoma was found.</Attribute>
              <Citation>
                <ID Source="PubMed">7670475</ID>
              </Citation>
              <XRef DB="OMIM" ID="155601" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">(In addition to the 19-bp deletion of p16, which is designated p16-Leiden, there is at least one familial hypercholesterolemia Leiden (143890.0041), factor V Leiden (612309.0001), apoE3 Leiden (107741.0006), and a hemoglobin Leiden (141900.0156).)</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Van der Velden et al. (1999) hypothesized that a tentative second tumor-related gene in 9p21 may also act as a modifier of melanoma risk conveyed by known CDKN2A mutations. To identify genetic modifiers for a known, 'primary' susceptibility gene, one would ideally need to study a large number of carriers of a single mutation in that primary gene. Dutch FAMMM families provided them with a unique opportunity for such studies, since the 19-bp founder deletion in exon 2 of the CDKN2A gene, p16-Leiden, segregated in most Dutch FAMMM families. The 36% cumulative incidence for melanoma in p16-Leiden carriers illustrated a high melanoma risk associated with this mutation but also suggested that environmental and/or genetic factors act as risk modifiers. Van der Velden et al. (1999) performed haplotype analysis for 9p21 using microsatellite markers in 6 p16-Leiden families originating from a founder population. In 2 families, p16-Leiden carriers shared an unexpectedly large founder haplotype (approximately 20 cM) around CDKN2A, mostly in the proximal direction. Melanoma-positive p16-Leiden carriers from these families showed this extensive proximal haplotype, compared with melanoma-negative p16-Leiden carriers from the same families. Additional p16-Leiden families less heavily affected with melanoma showed shorter haplotype sharing, excluding the region proximal of CDKN2A. The presence of a gene involved in melanoma susceptibility proximal to CDKN2A was corroborated by somatic deletions of 9p in tumors, which frequently did not include CDKN2A but a more proximal chromosomal region instead. The results provided a candidate region for further gene mapping in p16-negative 9p21-linked melanoma families and guided the search for risk modifiers in melanoma development.</Attribute>
              <Citation>
                <ID Source="PubMed">10400925</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Vasen et al. (2000) performed mutation analysis on 27 families with FAMMM syndrome and identified the CDKN2A-Leiden mutation in 19 families. They identified 86 patients with melanoma, and the second most frequent cancer was pancreatic carcinoma, which was observed in 15 patients from 7 families. The mean age at diagnosis of pancreatic carcinoma was 58 years, with a range from 38 to 77 years. Putative mutation carriers had an estimated cumulative risk of 17% for developing pancreatic carcinoma by age 75 years. In the 8 CDKN2A-Leiden-negative families, no cases of pancreatic carcinoma had occurred. The authors concluded that individuals with the CDKN2A-Leiden mutation show an enormous risk of developing pancreatic cancer (see 606719).</Attribute>
              <Citation>
                <ID Source="PubMed">10956390</ID>
              </Citation>
              <XRef DB="OMIM" ID="606719" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Schneider-Stock et al. (2003) found the p16-Leiden mutation in heterozygous state in the blood and all 3 tumors of a man who was diagnosed at age 54 years with simultaneous development of 3 carcinomas of the pharynx and oral cavity. The patient neither smoked more than 5 cigarettes daily nor abused alcohol. Both his parents and his only sister died of cancer very early (the mother of gynecologic cancer, the father of liver carcinoma, and the sister of leukemia).</Attribute>
              <Citation>
                <ID Source="PubMed">12549483</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Harinck et al. (2012) identified the Leiden mutation (225_243del) in 5 Dutch families ascertained for familial clustering of pancreatic cancer. Four of the families with the Leiden mutation had members who developed melanoma. In the fifth family, only pancreatic cancer segregated with mutation status; no cases of melanoma were noted. Harinck et al. (2012) concluded that the CDKN2A gene should be analyzed in families with pancreatic cancer, even if melanoma is not present.</Attribute>
              <Citation>
                <ID Source="PubMed">22636603</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDKN2A" />
          </GeneList>
          <Name>CDKN2A, 19-BP DEL, NT225</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">19-BP DEL, NT225</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="600160.0003" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">MELANOMA-PANCREATIC CANCER SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="30234" TraitType="Disease" MappingType="Name" MappingValue="MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 2" MappingRef="Preferred">
        <MedGen CUI="C1835044" Name="Melanoma, cutaneous malignant, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="30236" TraitType="Disease" MappingType="Name" MappingValue="MELANOMA-PANCREATIC CANCER SYNDROME" MappingRef="Alternate">
        <MedGen CUI="C1838547" Name="Melanoma-pancreatic cancer syndrome" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="3" DateDeleted="2019-12-02">SCV000030237</Accession>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

